ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen Liu

Maximizing the Potential of Immunotherapy in Unresectable Stage III NSCLCПодробнее

ARROW: an update on the registrational studyПодробнее

ARROW points the way for RET fusion-positive NSCLC treatment | Stephen LiuПодробнее

Pralsetinib in Chinese patients with advanced RET fusion+ NSCLCПодробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

RET fusion-positive mNSCLC: selpercatinib and pralsetinibПодробнее

ARROW study: pralsetinib in RET fusion+ tumorsПодробнее

ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumorsПодробнее

ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumorsПодробнее

Pralsetinib for Advanced or Metastatic RET-Altered Thyroid Cancer with Dr. Vivek SubbiahПодробнее

RET Fusion Treatment: Pralsetinib - Targeted Therapies in Lung Cancer 2023Подробнее

The Future of RET+ NSCLC Treatment - Targeted Therapies in Lung Cancer 2023Подробнее

Safety and Toxicity of Selpercatinib Versus Pralsetinib - Targeted Therapies in Lung Cancer 2023Подробнее

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions in NSCLCПодробнее

ASCO 2021 - Blueprint Medicines - ARROW Study Updated ResultsПодробнее

RET fusion-positive NSCLC: Delivering targeted treatment | Panel discussionПодробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

Next Steps in Treating ALK+ mNSCLCПодробнее